Literature DB >> 26739055

Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.

Philip T Lange1, Eric J Darrah1, Emily P Vonderhaar2, Wadzanai P Mboko1, Michaela M Rekow1, Shailendra B Patel3, Duska J Sidjanin4, Vera L Tarakanova5.   

Abstract

UNLABELLED: The cholesterol synthesis pathway is a ubiquitous cellular biosynthetic pathway that is attenuated therapeutically by statins. Importantly, type I interferon (IFN), a major antiviral mediator, also depresses the cholesterol synthesis pathway. Here we demonstrate that attenuation of cholesterol synthesis decreases gammaherpesvirus replication in primary macrophages in vitro and reactivation from peritoneal exudate cells in vivo. Specifically, the reduced availability of the intermediates required for protein prenylation was responsible for decreased gammaherpesvirus replication in statin-treated primary macrophages. We also demonstrate that statin treatment of a chronically infected host attenuates gammaherpesvirus latency in a route-of-infection-specific manner. Unexpectedly, we found that the antiviral effects of statins are counteracted by type I IFN. Our studies suggest that type I IFN signaling counteracts the antiviral nature of the subdued cholesterol synthesis pathway and offer a novel insight into the utility of statins as antiviral agents. IMPORTANCE: Statins are cholesterol synthesis inhibitors that are therapeutically administered to 12.5% of the U.S. POPULATION: Statins attenuate the replication of diverse viruses in culture; however, this attenuation is not always obvious in an intact animal model. Further, it is not clear whether statins alter parameters of highly prevalent chronic herpesvirus infections. We show that statin treatment attenuated gammaherpesvirus replication in primary immune cells and during chronic infection of an intact host. Further, we demonstrate that type I interferon signaling counteracts the antiviral effects of statins. Considering the fact that type I interferon decreases the activity of the cholesterol synthesis pathway, it is intriguing to speculate that gammaherpesviruses have evolved to usurp the type I interferon pathway to compensate for the decreased cholesterol synthesis activity.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26739055      PMCID: PMC4794672          DOI: 10.1128/JVI.02277-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene.

Authors:  H Shimano; I Shimomura; R E Hammer; J Herz; J L Goldstein; M S Brown; J D Horton
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Interferon regulatory factor 1 restricts gammaherpesvirus replication in primary immune cells.

Authors:  Wadzanai P Mboko; Bryan C Mounce; Joseph Emmer; Eric Darrah; Shailendra B Patel; Vera L Tarakanova
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

3.  Establishment and maintenance of long-term murine gammaherpesvirus 68 latency in B cells in the absence of CD40.

Authors:  David O Willer; Samuel H Speck
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.

Authors:  Meredith L Vandermeer; Ann R Thomas; Laurie Kamimoto; Arthur Reingold; Ken Gershman; James Meek; Monica M Farley; Patricia Ryan; Ruth Lynfield; Joan Baumbach; William Schaffner; Nancy Bennett; Shelley Zansky
Journal:  J Infect Dis       Date:  2011-12-13       Impact factor: 5.226

5.  Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Authors:  Jin Ye; Chunfu Wang; Rhea Sumpter; Michael S Brown; Joseph L Goldstein; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

6.  Repression of BK virus infection of human renal proximal tubular epithelial cells by pravastatin.

Authors:  Takahito Moriyama; Andrey Sorokin
Journal:  Transplantation       Date:  2008-05-15       Impact factor: 4.939

7.  Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication.

Authors:  Tohti Amet; Mizuho Nonaka; Md Zahidunnabi Dewan; Yasunori Saitoh; Xiaohua Qi; Shizuko Ichinose; Naoki Yamamoto; Shoji Yamaoka
Journal:  Microbes Infect       Date:  2008-01-20       Impact factor: 2.700

8.  Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice.

Authors:  Brigitte Glück; Michaela Schmidtke; Mario Walther; Astrid Meerbach; Peter Wutzler
Journal:  J Med Virol       Date:  2013-08-07       Impact factor: 2.327

9.  Simvastatin modulates cellular components in influenza A virus-infected cells.

Authors:  Parvaneh Mehrbod; Mohd Hair-Bejo; Tengku Azmi Tengku Ibrahim; Abdul Rahman Omar; Mohamed El Zowalaty; Zahra Ajdari; Aini Ideris
Journal:  Int J Mol Med       Date:  2014-04-28       Impact factor: 4.101

10.  Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(alpha) and IL-1, and by the Epstein-Barr virus transforming protein LMP1.

Authors:  A Puls; A G Eliopoulos; C D Nobes; T Bridges; L S Young; A Hall
Journal:  J Cell Sci       Date:  1999-09       Impact factor: 5.285

View more
  7 in total

Review 1.  Chewing the Fat: The Conserved Ability of DNA Viruses to Hijack Cellular Lipid Metabolism.

Authors:  Philip T Lange; Michael Lagunoff; Vera L Tarakanova
Journal:  Viruses       Date:  2019-01-29       Impact factor: 5.048

2.  Cholesterol Biosynthesis Modulates CSFV Replication.

Authors:  Xiaodong Zou; Feng Lin; Yang Yang; Jiahuan Chen; Huanyu Zhang; Linquan Li; Hongsheng Ouyang; Daxin Pang; Xiaochun Tang
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

Review 3.  Modulating cholesterol-rich lipid rafts to disrupt influenza A virus infection.

Authors:  Yu-Jyun Li; Chi-Yuan Chen; Jeng-How Yang; Ya-Fang Chiu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

4.  Low-Density Lipoprotein Receptor Suppresses the Endogenous Cholesterol Synthesis Pathway To Oppose Gammaherpesvirus Replication in Primary Macrophages.

Authors:  C A Aurubin; D A Knaack; D Sahoo; V L Tarakanova
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

5.  The liver X receptor agonist LXR 623 restricts flavivirus replication.

Authors:  Luwanika Mlera; Danielle K Offerdahl; David W Dorward; Aaron Carmody; Abhilash I Chiramel; Sonja M Best; Marshall E Bloom
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

6.  Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.

Authors:  Punya Shrivastava-Ranjan; Mike Flint; Éric Bergeron; Anita K McElroy; Payel Chatterjee; César G Albariño; Stuart T Nichol; Christina F Spiropoulou
Journal:  MBio       Date:  2018-05-01       Impact factor: 7.867

7.  Liver X Receptors Suppress Activity of Cholesterol and Fatty Acid Synthesis Pathways To Oppose Gammaherpesvirus Replication.

Authors:  P T Lange; C Schorl; D Sahoo; V L Tarakanova
Journal:  mBio       Date:  2018-07-17       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.